Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c

November 7, 2016 4:29 PM EST

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $31.9 million versus the consensus estimate of $33.86 million.


Halozyme Therapeutics sees 2016 revenue of $145-150 million, versus the consensus of $146.6 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment